<doc>
  <docmeta id="113hr2085ih">
    <bill congress="113" type="hr" number="2085" version="ih"/>
    <revision size="11710" annotations="0" status="complete" id="3" commit-time="2013-07-22T19:17:26Z" committer="mbohmer" doc="113hr2085ih/3.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H8B8E35A8353D4BA8975FFE8615F57707" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HR 2085 IH: Diagnostic Innovation Testing and Knowledge Advancement Act of 2013</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2013-05-22</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 2085</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20130522">May 22, 2013</action-date>
			<action-desc>
        <sponsor name-id="R000580">Mr. Roskam</sponsor> (for
			 himself, <cosponsor name-id="N000015">Mr. Neal</cosponsor>,
			 <cosponsor name-id="L000567">Mr. Lance</cosponsor>,
			 <cosponsor name-id="K000188">Mr. Kind</cosponsor>, <cosponsor name-id="G000558">Mr. Guthrie</cosponsor>, <cosponsor name-id="P000594">Mr.
			 Paulsen</cosponsor>, and <cosponsor name-id="T000462">Mr. Tiberi</cosponsor>)
			 introduced the following bill; which was referred to the
			 <committee-name committee-id="HIF00">Committee on Energy and
			 Commerce</committee-name>, and in addition to the Committee on
			 <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a
			 period to be subsequently determined by the Speaker, in each case for
			 consideration of such provisions as fall within the jurisdiction of the
			 committee concerned</action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To create incentive for innovative diagnostics by
		  improving the process for determining Medicare payment rates for new
		  tests.</official-title>
	</form>
	<legis-body id="HDFAA80B374CE45919696E530C9F52E67" style="OLC">
		<section id="H31DA95BE0C4948FD8E9A71449C42583F" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the
			 <quote>
          <short-title>Diagnostic Innovation Testing and
			 Knowledge Advancement Act of 2013</short-title>
        </quote>.</text>
		</section>
    <section commented="no" id="H466E8322873E4F02ADD39DCEB4BE9F5D">
      <enum>2.</enum>
      <header>Creating
			 incentives for innovative diagnostics</header>
			<subsection commented="no" id="H11AE3205FF5542659588FE7D5BF04150">
        <enum>(a)</enum>
        <header>Improvements To
			 process for determining fee schedule amounts for new tests</header>
				<paragraph commented="no" id="H7E4E96364E7C48289B9C55BA19B80B18">
          <enum>(1)</enum>
          <header>Clarifying
			 factors for rate-setting</header>
          <text display-inline="yes-display-inline">In
			 determining the payment amount under gapfilling procedures (as described in
			 <external-xref legal-doc="regulation" parsable-cite="cfr/42/414.508">section 414.508(b)</external-xref> of title 42, Code of Federal Regulations, or any successor
			 regulation to such section) for new clinical diagnostic laboratory tests under
			 <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Social Security Act/s:1833/ss:h/p:8">section 1833(h)(8) of the Social Security Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/1395l">
                <cato:entity-ref entity-type="uscode" value="usc/42/1395l/h/8">42 U.S.C. 1395l(h)(8)</cato:entity-ref>
              </external-xref>)</cato:entity>, the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary of Health and Human Services</cato:entity-ref> (in this section referred to as the
			 <term>Secretary</term>) shall take into account, as applicable and available,
			 the following factors with respect to such a new test:</text>
					<subparagraph commented="no" id="H9449F27CBA7F4BA78864CF75D245EC71">
            <enum>(A)</enum>
            <header>Impact on
			 patient care</header>
            <text display-inline="yes-display-inline">The impact of
			 the new test on patient care, patient management, or patient treatment.</text>
					</subparagraph>
          <subparagraph commented="no" id="H69B4238F10674F6D8656AEE5E853DEE4">
            <enum>(B)</enum>
            <header>Technical
			 characteristics</header>
            <text display-inline="yes-display-inline">The technical
			 characteristics of the new test, and the resources required to develop,
			 validate, and perform the new test.</text>
					</subparagraph>
          <subparagraph commented="no" id="H6F93FD7B4450441F89151D431966234F">
            <enum>(C)</enum>
            <header>Claims
			 data</header>
            <text display-inline="yes-display-inline">Data from claims for
			 which payment is made under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/t:XVIII/pt:B">part B of title XVIII of the Social Security
			 Act</cato:entity-ref>.</text>
					</subparagraph>
          <subparagraph commented="no" id="H3ECD06B7089D49868348E62820EEAF80">
            <enum>(D)</enum>
            <header>Laboratory
			 charges</header>
            <text display-inline="yes-display-inline">Amounts charged by
			 laboratories to self-pay patients for the new test.</text>
					</subparagraph>
          <subparagraph commented="no" id="HCFC92E92611948698F709B09181AFF78">
            <enum>(E)</enum>
            <header>Private
			 insurance rates</header>
            <text display-inline="yes-display-inline">Amounts paid
			 to laboratories for such new test under private health insurance coverage
			 offered in the group market and the individual market.</text>
					</subparagraph>
          <subparagraph commented="no" id="H802C457BF9184EEB8AE6FA2B4196AAF7">
            <enum>(F)</enum>
            <header>Advisory panel
			 recommendations</header>
            <text display-inline="yes-display-inline">The findings
			 and recommendations of the independent advisory panel convened under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Diagnostic Innovation Testing and Knowledge Advancement Act of 2013/s:2/ss:a/p:2" proposed="true">paragraph
			 (2)</cato:entity-ref> with respect to that new test and any comments received during the open
			 meeting of the advisory panel.</text>
					</subparagraph>
          <subparagraph commented="no" id="HD5CB526B05234C53939A72FF29A5201B">
            <enum>(G)</enum>
            <header>Additional
			 factors</header>
            <text display-inline="yes-display-inline">Such other factors as
			 the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may specify.</text>
					</subparagraph>
        </paragraph>
        <paragraph commented="no" id="H337923CDF1EC489792A59FF34B4D20A2">
          <enum>(2)</enum>
          <header>Input from
			 patients, clinicians, and technical experts</header>
					<subparagraph commented="no" id="H7302828147664231A7D660D352D5AFE9">
            <enum>(A)</enum>
            <header>Requirement for
			 independent advisory panel</header>
            <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall convene an independent
			 advisory panel from which the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall request information and
			 recommendations regarding any new test (as referred to under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1833/ss:h/p:8/sp:A">subparagraph (A)</cato:entity-ref>
			 of <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                <cato:entity-ref entity-type="act" value="Social Security Act/s:1833/ss:h/p:8">section 1833(h)(8) of the Social Security Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/1395l">
                  <cato:entity-ref entity-type="uscode" value="usc/42/1395l/h/8">42 U.S.C. 1395l(h)(8)</cato:entity-ref>
                </external-xref>)</cato:entity>) for
			 which payment is made under such section, including technical, clinical, and
			 quality information.</text>
					</subparagraph>
          <subparagraph commented="no" id="H6E7CE64630F24F0E8432B46E9DAF00AB">
            <enum>(B)</enum>
            <header>Composition of
			 independent advisory panel</header>
            <text display-inline="yes-display-inline">Subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Diagnostic Innovation Testing and Knowledge Advancement Act of 2013/s:2/ss:a/p:2/sp:D" proposed="true">subparagraph (D)</cato:entity-ref>, the
			 independent advisory panel shall be comprised of 19 members, including—</text>
						<clause commented="no" id="HB98BC8842C3A43F1808E0E217AF7FED2">
              <enum>(i)</enum>
              <text display-inline="yes-display-inline">7 individuals with expertise and experience
			 with clinical diagnostic laboratory tests including expertise in the technical
			 characteristics of the new test as well as expertise in the requirements to
			 develop, validate, and perform the new test;</text>
						</clause>
            <clause commented="no" id="H59AF1AE16BFB4EB3AF9C1AA5FEB83F52">
              <enum>(ii)</enum>
              <text>3 representatives
			 of patients, including a patient representative for rare disorders;</text>
						</clause>
            <clause commented="no" id="HAEFCEB13BE814318A481D9BA02A01F56">
              <enum>(iii)</enum>
              <text>3 clinicians who
			 use results of the new test in patient care;</text>
						</clause>
            <clause commented="no" id="H6276A868169B4E3D871C6C0F62F974BE">
              <enum>(iv)</enum>
              <text>2
			 laboratorians;</text>
						</clause>
            <clause commented="no" id="HC0040700AEC94DB5A2734331DFBA4A9A">
              <enum>(v)</enum>
              <text>2 individuals with
			 expertise in the area of pharmacoeconomics or health technology assessment;
			 and</text>
						</clause>
            <clause commented="no" id="H356687AD1B9D42949FD861EECF93AEF4">
              <enum>(vi)</enum>
              <text>2 individuals
			 with expertise on the impact of new tests on quality of patient care, including
			 genetic counselors.</text>
						</clause>
          </subparagraph>
          <subparagraph commented="no" id="HBF651870CB2741A7ADA02642E7361004">
            <enum>(C)</enum>
            <header>Terms</header>
            <text display-inline="yes-display-inline">Subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Diagnostic Innovation Testing and Knowledge Advancement Act of 2013/s:2/ss:a/p:2/sp:D" proposed="true">subparagraph (D)</cato:entity-ref>, a member of
			 the panel shall be appointed to serve a term of 6 years, except with respect to
			 the members first appointed, whose terms of appointment shall be staggered
			 evenly over 2-year increments.</text>
					</subparagraph>
          <subparagraph id="HFDC68E2F28E34567B48591490C876D45">
            <enum>(D)</enum>
            <header>Temporary
			 appointment of experts</header>
            <text>Insofar as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines with
			 respect to a new test that there are an insufficient number of members of the
			 panel with expertise with respect to that specific test, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may
			 appoint individuals who have expertise pertaining to the new test involved to
			 serve on the panel.</text>
					</subparagraph>
          <subparagraph commented="no" id="HCD7CDC8D58344A91938987BC66C250AA">
            <enum>(E)</enum>
            <header>Open
			 meetings</header>
            <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
			 receive or review the findings and recommendations of the independent advisory
			 panel with respect to the new tests described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Diagnostic Innovation Testing and Knowledge Advancement Act of 2013/s:2/ss:a/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> involved
			 during a meeting open to the public and provide opportunity for public
			 comment.</text>
					</subparagraph>
          <subparagraph commented="no" id="HDF675EF3447240638D8659A9D3360DBD">
            <enum>(F)</enum>
            <header>Clarification of
			 authority of secretary to consult carriers</header>
            <text display-inline="yes-display-inline">Nothing in this section shall be construed
			 as affecting the authority of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> to consult with appropriate
			 Medicare administrative contractors.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="H03B94231358D4D028835110EE503E60A">
          <enum>(3)</enum>
          <header>Justification
			 for payment determinations</header>
					<subparagraph id="H031DF1799EFA4675BB319986981C56C7">
            <enum>(A)</enum>
            <header>Initial
			 justification</header>
            <text>With respect to decisions regarding payments made
			 under the clinical laboratory fee schedule for new clinical diagnostic
			 laboratory tests, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall publicly provide a justification for the
			 payment basis and payment rate determination, including a detailed summary of
			 the information submitted to, or obtained by, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> regarding the
			 factors specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Diagnostic Innovation Testing and Knowledge Advancement Act of 2013/s:2/ss:a/p:1" proposed="true">paragraph (1)</cato:entity-ref>, such that interested stakeholders can
			 readily understand the Secretary’s rationale for the payment basis and rate
			 determinations.</text>
					</subparagraph>
          <subparagraph id="HAA397B5EA1DE4DEA8D45A41C6648D2BE">
            <enum>(B)</enum>
            <header>Reconsideration
			 period</header>
            <text>After providing such justification for a payment basis and
			 payment rate determination, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall provide for a reasonable period
			 of reconsideration to receive any appeal of the determination and to evaluate
			 any additional information received regarding the justification and the factors
			 specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Diagnostic Innovation Testing and Knowledge Advancement Act of 2013/s:2/ss:a/p:1" proposed="true">paragraph (1)</cato:entity-ref>.</text>
					</subparagraph>
          <subparagraph id="HE5DCC1DF985A42A39B5732E4E2870263">
            <enum>(C)</enum>
            <header>Final
			 determination</header>
            <text>After the period of reconsideration the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
			 shall make a final payment basis and payment rate determination and provide a
			 justification for such final determination explaining what additional
			 information was evaluated during the reconsideration and how such information
			 was taken into account with respect to the final determination. Nothing in this
			 paragraph shall be construed as authorizing the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> to reveal proprietary
			 information which is otherwise prohibited from disclosure under law.</text>
					</subparagraph>
        </paragraph>
      </subsection>
      <subsection commented="no" id="HF15060821AB5410DA425B4E060D246CC">
        <enum>(b)</enum>
        <header>Process for
			 assignment of temporary codes for diagnostic tests</header>
        <text display-inline="yes-display-inline">The
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish a process for application for the assignment of a
			 temporary national HCPCS code to uniquely identify a diagnostic test until a
			 permanent national HCPCS code is available for assignment to that test.
			 Assignments of a temporary national HCPCS code shall occur on a quarterly
			 basis. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall provide public notice through the Centers for
			 Medicare &amp; Medicaid Services Web site of applications made for such
			 temporary national HCPCS codes. Upon assignment of a temporary code under this
			 process, the Secretary shall treat such test as a new test for purposes of
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1833/ss:h/p:8">section 1833(h)(8) of the Social Security Act</cato:entity-ref>.</text>
			</subsection>
      <subsection commented="no" id="H2D75D68745DA4203B2E6D0E0270F8D50">
        <enum>(c)</enum>
        <header>Development of
			 further improvements in rate-Setting processes</header>
        <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall analyze the process
			 used for the gapfilling procedure used in determining payment amounts for new
			 clinical diagnostic laboratory tests under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1833/ss:h/p:8">section 1833(h)(8) of the Social
			 Security Act</cato:entity-ref>. Taking into account the changes made by this section, the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall identify further changes to improve the accuracy and
			 appropriateness of resulting rates and the openness, transparency, and
			 predictability of the process. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall examine what and how many
			 entities should perform gapfilling, under contract or otherwise, and how to
			 ensure that the process is informed by appropriate expertise and proceeds in a
			 transparent and accountable manner. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall implement improvements
			 in the process, insofar as these are possible under the law through
			 regulations, after public notice and opportunity for comment. For changes the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines would require a change in law, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
			 transmit recommendations to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Speaker of the House of Representatives" entity-parent-id="0050">Speaker of the House</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="President of the Senate" entity-parent-id="0010">President of the
			 Senate</cato:entity-ref> not later than July 1, 2014.</text>
			</subsection>
      <subsection id="HAABCA044A21346ECAB04A3BAC27BD3E9">
        <enum>(d)</enum>
        <header>Definitions</header>
        <text display-inline="yes-display-inline">For purposes of this section:</text>
				<paragraph id="H72866D5FA6E7421689704BEBA190AB45">
          <enum>(1)</enum>
          <header>New clinical
			 diagnostic laboratory tests</header>
          <text display-inline="yes-display-inline">The term <term>new clinical diagnostic
			 laboratory test</term> means a clinical diagnostic laboratory test—</text>
					<subparagraph id="H34D4ADF6FDDB4154B75C22E629659A75">
            <enum>(A)</enum>
            <text>that is assigned a
			 new or substantially revised code on or after January 1, 2013; or</text>
					</subparagraph>
          <subparagraph id="H75B40DA2BBC2475AB730C6DA1C688A6E">
            <enum>(B)</enum>
            <text>for which a
			 temporary national HCPCS code is granted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Diagnostic Innovation Testing and Knowledge Advancement Act of 2013/s:2/ss:b" proposed="true">subsection (b)</cato:entity-ref> on or after
			 January 1, 2014.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="HCE9CEFE03F0044FFAA6775FEAA9FB8AF">
          <enum>(2)</enum>
          <header>Self-pay
			 patient</header>
          <text>The term <term>self-pay patient</term> means, with
			 respect to a health care item or service, an individual who pays out of pocket
			 for such item or service and who does not have health insurance coverage for
			 such item or service.</text>
				</paragraph>
      </subsection>
      <subsection commented="no" id="H935C7461BDEF4749A27570C9137420BF">
        <enum>(e)</enum>
        <header>Effective
			 date</header>
				<paragraph id="HED0A8CE31D6C4D2298876803B78703F7">
          <enum>(1)</enum>
          <header>In
			 general</header>
          <text>Subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Diagnostic Innovation Testing and Knowledge Advancement Act of 2013/s:2/ss:e/p:2" proposed="true">paragraph (2)</cato:entity-ref>, this section shall take effect
			 on the date of enactment of this Act and shall apply with respect to new
			 clinical diagnostic laboratory tests.</text>
				</paragraph>
        <paragraph id="H48F53B4DD0364047A7DA6B0F408673AB">
          <enum>(2)</enum>
          <header>Application of
			 justifications to current rate determinations</header>
          <text>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Diagnostic Innovation Testing and Knowledge Advancement Act of 2013/s:2/ss:a/p:3" proposed="true">Subsection (a)(3)</cato:entity-ref>
			 shall apply to payment basis and payment rate determinations made on or after
			 January 1, 2013.</text>
				</paragraph>
      </subsection>
    </section>
  </legis-body>
</bill>
</doc>